Topline Capital Management LLC Invests $6.68 Million in Certara, Inc. $CERT

Topline Capital Management LLC purchased a new stake in Certara, Inc. (NASDAQ:CERT) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 546,471 shares of the company’s stock, valued at approximately $6,678,000. Certara makes up approximately 1.1% of Topline Capital Management LLC’s investment portfolio, making the stock its 20th largest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Associated Banc Corp lifted its stake in Certara by 9.7% in the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after purchasing an additional 1,051 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Certara by 2.5% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock worth $535,000 after buying an additional 1,136 shares during the last quarter. Versant Capital Management Inc increased its holdings in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after buying an additional 1,153 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares in the last quarter. Finally, Corient Private Wealth LLC lifted its stake in shares of Certara by 11.1% in the 2nd quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock valued at $144,000 after acquiring an additional 1,232 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Price Performance

Shares of CERT opened at $6.65 on Friday. The firm has a market cap of $1.06 billion, a PE ratio of -665.00 and a beta of 1.50. Certara, Inc. has a 52-week low of $6.04 and a 52-week high of $15.38. The business’s 50 day moving average price is $7.98 and its two-hundred day moving average price is $9.62. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $103.65 million for the quarter, compared to analyst estimates of $103.23 million. Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period last year, the business earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, equities analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CERT shares. Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a report on Sunday, February 15th. TD Cowen reaffirmed a “buy” rating on shares of Certara in a report on Thursday, February 26th. Rothschild & Co Redburn set a $10.00 target price on Certara in a research report on Friday, November 21st. KeyCorp cut their price target on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Certara presently has a consensus rating of “Hold” and an average target price of $11.10.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.